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In a number of biological studies, the raw gene expression data are not usually published due to different
causes, such as data privacy and patent rights. Instead, signiﬁcant gene lists with fold change values are
usually provided in most studies. However, due to variations in data sources and proﬁling conditions,
only a small number of common signiﬁcant genes could be found among similar studies. Moreover, tra-
ditional gene set based analyses that consider these genes have not taken into account the fold change
values, which may be important to distinguish between the different levels of signiﬁcance of the genes.
Human embryonic stem cell derived cardiomyocytes (hESC-CM) is a good representative of this category.
hESC-CMs, with its role as a potentially unlimited source of human heart cells for regenerative medicine,
have attracted the attentions of biological and medical researchers. Because of the difﬁculty of acquiring
data and the resulting expenses, there are only a few related hESC-CM studies and few hESC-CM gene
expression data are provided. In view of these challenges, we propose a new Gene Set Enrichment
Ensemble (GSEE) approach to perform gene set based analysis on individual studies based on signiﬁcant
up-regulated gene lists with fold change data only. Our approach provides both explicit and implicit ways
to utilize the fold change data, in order to make full use of scarce data. We validate our approach with
hESC-CM data and fetal heart data, respectively. Experimental results on signiﬁcant gene lists from dif-
ferent studies illustrate the effectiveness of our proposed approach.
 2015 Elsevier Inc. All rights reserved.1. Introduction
In recent years, gene set analysis methods are widely adopted in
bioinformatics studies to understand gene regulatory mechanisms
and related biological processes [1–4], which are usually recog-
nized to be more effective to search for consensus results among
different studies than single gene analysis methods. In general,
these tools adopt speciﬁc gene set collections as references, and
perform statistical analysis on these gene sets by comparison with
the results of multiple random permutations. According to the dif-
ference of the input data, these tools can be divided into two cat-
egories: (1) microarray data based methods, which in general
have access to the full data matrices. Representative examples
include GSEA [1], SAM-GS [5], SAFE [6] and (2) signiﬁcant gene list
based methods, which adopt a small or large signiﬁcant gene list asinput. Representative examples include FuncAssociate [7], Bingo
[8], WebGestalt [9] and DAVID [2].
However, in a number of biological studies, the raw gene
expression data are not published due to different causes, such
as data privacy and patent rights. Instead, signiﬁcant gene lists
with fold change values are usually provided in most studies.
Human embryonic stem cell derived cardiomyocytes (hESC-CM)
is a good representative of this category. Recently, improved isola-
tion techniques of human embryonic stem cell (hESC) lines lead to
tremendous progress of stem cell studies. Human embryonic stem
cells, with its role as a potentially unlimited source of human cells
for regenerative medicine, have attracted the interests of biological
and medical researchers. Currently, investigation on human
embryonic stem derived cardiomyocytes (hESC-CMs) is regarded
as highly important in related hESC studies. However, due to the
difﬁculty of data acquisition, there are only a small number of
related individual studies from different cell lineages, with differ-
ent purity levels of the ﬁnal cell preparations [10–15]. Among
these studies, traditional functional proﬁling has been widely
adopted to understand the gene regulatory mechanisms and
biological processes that control the differentiation of human
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Beqqali et al. [10] performed the ﬁrst comparison of hESCs with
their cardiac derivatives. Synnergren et al. [11] identiﬁed 540
up-regulated marker genes and 40 down-regulated ones in
hESC-derived CM clusters compared to undifferentiated hESCs.
Cao et al. studied the spectrum of changes that occur during CM
differentiation and also compared enriched hESC-VCMs with fetal
heart cells [12]. Xu et al. used puriﬁed hESC-CMs and identiﬁed
1311 cardiac-enriched genes [13]. Synnergren et al. analyzed the
similarity between hESC-CM clusters with reference samples from
fetal and adult heart tissues, and focused on ion channel and
Ca2þ-handling genes [14]. Different gene set enrichment methods
with different gene set collections were also adopted in related
hESC-CM studies. Speciﬁcally, Gene Ontology Tree Machine
Classiﬁcation was used in [10] to assign signiﬁcant genes into 12
rough categories. Gene Ontology overrepresentation analysis was
performed using Fisher’s Exact test and High Throughput
GOMiner software [12]. Signiﬁcant gene sets were identiﬁed using
the DAVID bioinformatics tool at level 5 in the Gene Ontology
annotation hierarchy in [11,14]. Similar analysis was performed
in [13] using a commercial tool called GeneSpring. Due to the dif-
ﬁculty and the expense of acquiring hESC-CM data, a comparative
investigation on these closely related studies is in acute need. More
speciﬁcally, a comparison of signiﬁcantly enriched gene sets of
these hESC-CM studies will undoubtedly shed light on further
required works in bioinformatics. However, instead of full gene
expression data, most of the proposed studies only provided
incomplete signiﬁcant gene lists with fold change data
[10,11,13]. As there are usually only a small number of commonly
signiﬁcant genes among different studies, it is difﬁcult to perform a
comparative study among them in the form of a meta-analysis, as
in other domains such as cancer gene proﬁling. As a result, the
main review articles [16,17, Ch. 19, p. 343] usually provided qual-
itative analysis for only a small number of individual genes. On the
other hand, because of the diverse gene set analysis methods and
the various gene set collections, it is not practical to compare the
results of these publications. Moreover, not all the details of the
enriched gene sets are publicly provided in these studies. As a
result, the literature [16,17, Ch. 19, p. 343] could only provide brief
descriptions of a few results on gene set based analysis. In addition,
due to the scarcity and the heterogeneous characters of hESC-CM
data, currently there are not many works that compare hESC-CM
studies in terms of gene set based analysis. Moreover, in order to
make full use of the scarce hESC-CM data, the difference of the fold
change data of different signiﬁcant genes should not be ignored.
More speciﬁcally, there are no reasons to make the simple hypoth-
esis that a gene with a large fold change (FC) (e.g., FC = 100) plays a
similar role as that with a small one (FC = 2). However, this is usu-
ally ignored by most of the available gene set analysis methods. In
addition, manymethods implemented in online tools and commer-
cial software, do not provide effective ways for users to adopt their
own gene set collections as references. This will unavoidably pre-
vent users to effectively compare hESC-CM studies.
In view of the challenges to perform a suitable gene set based
analysis on heterogeneous data, we propose to use signiﬁcant gene
lists. Our motivation to adopt signiﬁcant gene lists is because we
can readily identify them from those studies with full data matri-
ces even if the list is not explicitly provided. To perform gene set
based analysis, we propose a new method, called Gene Set
Enrichment Ensembles (GSEE). This approach can be directly
applied to extracted signiﬁcant gene lists and their corresponding
fold change (FC) data to evaluate the signiﬁcance of related gene
sets, such that the results of different studies can be effectively
compared. We have applied this framework to a number of differ-
ent data types, including hESC-CM and fetal heart data.In addition, it is notable that meta-analysis for commonly sig-
niﬁcant genes from multiple related studies has recently attracted
great attention [18–20]. However, to our best knowledge, these
recent techniques focus on marker genes, and there is no reported
progress on applying these approaches to commonly enriched gene
sets. Interestingly, our GSEE method can be extended in a straight-
forward way to gene set based meta-analysis by aggregating
knowledge from different studies in a natural manner, which is
widely adopted in studies of cluster ensemble work [21–32].
Another notable difference is that our GSEE method can use only
signiﬁcant gene lists, which is more general and thus can be appli-
cable in more scenarios.
1.1. Contribution of this paper
The contributions of this study include: (a) From a computa-
tional perspective, we propose a new Gene Set Enrichment
Ensemble (GSEE) method based on signiﬁcant gene lists and their
fold change (FC) data. Our method utilizes the FC data to implicitly
assign different weights for genes with different degree of signiﬁ-
cance. In addition, our method provides the function to adopt
user-deﬁned gene set collections, which is thus more applicable
to cases where users might choose their own reference data.
Finally, our GSEE method can be easily extended to the case of
meta-analysis based on multiple related studies. (b) To our best
knowledge, from the perspective of biological analysis, we perform
the ﬁrst investigation of different hESC-CM studies with detailed
gene set analysis.
1.2. Organization of this paper
The rest of the paper is organized as follows. Section 2 presents
the Gene Set Enrichment Ensemble (GSEE) method. Section 3
describes the experimental results. Section 4 concludes the paper.2. Proposed method
The key problem is how to model gene sets with respect to the
signiﬁcant gene lists with fold change data. We proposed to evalu-
ate the gene set enrichment based on different extents of gene pair
associations. Speciﬁcally, we propose a Gene Set Enrichment
Ensemble (GSEE) method, and design a new score scheme called
Adjusted Aggregation Score (AAS). We will ﬁrst introduce the gen-
eralized Adjusted Rand Index (ARI) for cluster ensembles [33–37],
from which the AAS score is motivated.
2.1. Generalized Adjusted Rand Index (ARI) for two similarity matrices
in cluster ensembles
Adjusted Rand Index (ARI) is one of the most well-known
clustering comparison measure, based on pairwise agreement
counting [33], as an improved version of the original Rand
Index [38]. Desirable properties of the ARI measure beyond the
Rand Index are investigated by a lot of related work [34–37].
In one of our recent works, ARI is generalized to evaluate the
consistency between two similarity matrix. Speciﬁcally, given
two N  N similarity matrices A and B, the generalized
Adjusted Rand Index between matrices (ARImm) is deﬁned as
follows [36]
s0 ¼
X
i;j;i–j
AijBij
2
; s1 ¼
X
i;j;i–j
Aij
2
s2 ¼
X
i;j;i–j
Bij
2
; s3 ¼ 2s1s2NðN  1Þ
ð1Þ
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0:5ðs1 þ s2Þ  s3 ð2Þ
For this measure, s0 is deﬁned in terms of the product of the
pairwise similarity of each entity pair between two similarity
matrices, and s3 is the expected value when these two similarity
matrices are constructed from two random cluster ensembles.
Motivated from the desirable properties of ARImm, we proposed
a novel Gene Set Enrichment Ensemble (GSEE) method to make full
use of signiﬁcant genes with fold change data. Similar to the ARI,
our proposed GSEE approach will be able to account for differences
in gene set size.
2.2. Gene Set Enrichment Ensemble (GSEE)
We design our Gene Set Enrichment Ensemble (GSEE) method
in a similar manner as cluster ensembles, by aggregating the signif-
icance extent of gene pairs with respect to different fold change
thresholds. Speciﬁcally, given a certain gene set collection
C ¼ fckgNCk¼1, we ﬁrst extract a combined list l which includes Nl
genes. We project the signiﬁcant expressed genes of the inspected
study into a gene-speciﬁc evidence matrix according to different
fold change (FC) threshold values. Speciﬁcally, given D FC threshold
values fFjgDj¼1, denoting by FCðgiÞ the fold change value of gene gi,
the Nl  D gene-speciﬁc evidence matrices can be computed as
follows:
Mij ¼
1 9FCðgiÞP Fj; j ¼ 1; . . . ;D
0 otherwise

ð3Þ
Given a particular gene set c ¼ fgigNi¼1 with N genes, we can
extract its N  D evidence matrix M by
½Mij ¼ mij ¼
1 9FCðgiÞP Fj; j ¼ 1; . . . ;D
0 otherwise

ð4Þ
Note thatM can also be extracted from the Nl  D gene-speciﬁc evi-
dence matrices by comparing the genes in the lists of c and l.
We compute the Aggregation Score (AS) of the lower triangular
entries of the matrix with an N  D secondary weight matrix W as
follows
ZASðMÞ ¼
XD
x¼1
Xx
y¼1
ðM WÞ0ðM WÞ ¼
XD
x¼1
Xx
y¼1
XN
i¼1
mixwixmiywiy ð5Þ
whereM W is the element-wise product of the twomatricesM and
W, and wij in the secondary weight matrix
W ¼ ½wijND ð6Þ
indicates the importance of gene gi in the fold change level j. In gen-
eral it is not practical to specify such a detailed weighting scheme. A
reasonable simpliﬁcation is to assign the same weight value for
genes above a particular fold change threshold, i.e.,
w1j ¼ w2j ¼    ¼ wnj ¼ wj; 8j ð7Þ
Note that this secondary weight matrix is optional, as all genes can
be given the same weight by making every entry in the matrix equal
to 1.
This preliminary Aggregation Score reﬂects both the evidence
matrices of different genes corresponding to different levels with
respect to various fold change thresholds, and the number of sig-
niﬁcant genes in a particular study. Notably, a gene with larger
FC value than the FC threshold Fj will appear at least j times in
the evidence matrix. Thus, genes with higher FC values will take
a more important role. However, this Aggregation Score is affected
by the size of the signiﬁcant gene set, as more genes will have a
higher chance to be signiﬁcantly expressed. In view of this issue,and inspired by the improvement of the Rand Index [38] in the
form of the general Adjusted Rand Index (ARI) [33–37], we design
an improved version of the above Aggregation Score, which is
referred to as the Adjusted Aggregation Score (AAS). In AAS, we
compare the difference of the Aggregation Score values between
a particular gene set and the expected score associated with a ran-
dom gene set, which is further normalized by the difference
between the maximum possible score value and the expected
score. Speciﬁcally, for the j-th fold change threshold Fj, the esti-
mated probability of a gene gi with a fold change value not smaller
than Fj (i.e., FCðgiÞP Fj) based on the gene-speciﬁc evidence
matrix can be computed as
q^j ¼
PNl
i¼1Mij
Nl
; j ¼ 1; . . . ;D ð8Þ
Thus the expected value of the AS score corresponding to a NR  D
random evidence matrix MR can be computed as
Z ¼ E
XD
x¼1
Xx
y¼1
XNR
i¼1
ðmixwxmiywyÞ
" #
 NR
XD
x¼1
Xx
y¼1
q^xwxq^ywy ð9Þ
where q^x; q^y are estimated up-regulation probabilities based on the
gene-speciﬁc evidence matrixM. The second step follows from the
approximation of the expected value based on the estimated prob-
abilities when NR is large. We can observe from Eq. (9) that the
score value is not zero, and is correlated to the size of the gene
set NR. As a result, we propose an Adjusted Aggregation Score
(AAS) score based on the evidence matrix. The maximum score
value corresponding to the evidence matrix M can be readily found
when all the entries are ones. Thus, the maximum score value is
computed as
Zmax ¼
XD
x¼1
Xx
y¼1
XN
i¼1
mixwxmiywy ¼ N
XD
x¼1
Xx
y¼1
wxwy ð10Þ
Therefore, the difference of the Aggregation Score values
between a particular gene set and the expected score associated
with a random gene set can be computed as
eZASðMÞ ¼ ZAS  Z
¼
XD
x¼1
Xx
y¼1
XN
i¼1
mixwxmiywy  N
XD
x¼1
Xx
y¼1
q^xwxq^ywy ð11Þ
The difference of the Aggregation Score values between the maxi-
mum possible one and the expected score can be computed as
eZmaxðMÞ ¼ Zmax  Z ¼ NXD
x¼1
Xx
y¼1
wxwy  N
XD
x¼1
Xx
y¼1
q^xwxq^ywy ð12Þ
The Adjusted Aggregation Score (AAS) score can thus be com-
puted as
ZAASðMÞ ¼
eZASðMÞeZmaxðMÞ ð13Þ2.3. Summary
The complete GSEE approach is summarized in Algorithm 1.2.4. Characteristics of the proposed GSEE method
Compared to conventional gene set analysis methods, our pro-
posed GSEE method has a number of advantages:
Table 1
Summaries of related hESC-CM studies. The shaded entries have only fold change data available and the un-shaded entries have the entire expression data set available.
Note: abbreviation in this table: CM = hESC-CM, CMC = hESC-CM Clusters.
1 http://www.geneontology.org/ontology/obo_format_1_0/gene_ontology.1_0.obo.
2 ftp://ftp.ebi.ac.uk/pub/databases/GO/goa/HUMAN/geneassociation.goahuman.gz.
3 http://www.broadinstitute.org/gsea/msigdb/collection_details.jsp.
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rather than the full microarray data, our GSEE method is readily
applicable to such types of data for gene set analysis.
 Compared with gene set analysis methods based on only signif-
icant gene lists, GSEE considers different contributions of genes
with different signiﬁcance by taking advantage of the fold
change data of signiﬁcant genes.
 Most of the conventional gene set analysis methods require per-
forming multiple random permutation trials. Our GSEE method
avoids this burden of computation time by comparing the com-
puted score with the expected score of a random gene set.
Therefore, the computational efﬁciency of GSEE is greatly
improved.
 GSEE can be easily used in meta-analysis of multiple studies by
aggregating evidence matrices frommultiple studies into a con-
sensus one, as those performed in cluster ensembles.
3. Experimental results
In this section, we conducted experiments on a number of
hESC-CM data and fetal heart data. We ﬁrst introduce our experi-
mental settings, including the data sets used, the parameter selec-
tions, the previous algorithms to be compared with, and the
evaluation metrics.
Algorithm 1. GSEE3.1. Experiment settings3.1.1. Studies of human embryonic stem cell-derived cardiomyocytes
We have collected data from related studies [10,11,13,12,14]
to detect the enriched genes and pathways for ESC-CM like cells
relative to ES cells, as shown in Table 1. Note that PG12CMC3w
and PG12CMC7w are extracted from the same study. We include
both of these two data sets from the same study for two reasons:
(i) full hESC-CM data sets are very scarce and (ii) these two data
sets are extracted in different ESC-CM periods (21d and 49d) and
investigation of hESC-CM in different development periods is
highly important. For the studies from the ﬁrst category
[10,11,13], there are only signiﬁcant gene lists provided, and
the corresponding methods and parameters adopted by the orig-
inal authors are reported in the column ‘Method and Parameter’
in Table 1. For the other studies, the basic fold change (FC)
threshold is set to the most typical cutoff value 2, in accordance
to those adopted in [10,13].
3.1.2. Extraction of gene set collection
We used version 1.1.2681 of the ﬁle gene ontology.1.0.obo
(Time stamp: 06:03:2012 19:30, downloaded from the GO ofﬁ-
cial web site1). We used the Homo Sapiens annotation ﬁle with
the version 1.225 of the ﬁle gene_association.goa human (Time
stamp: 06:03:2012, downloaded from the Gene Ontology
Annotation Database, UniProt-GOA2). We constructed the gene
set collection using a similar method as is adopted for the GSEA
ofﬁcial MsigDB C5 gene sets.3 Speciﬁcally, only entries associated
with the following evidence codes were included: Inferred from
Direct Assay (IDA), IPI (Inferred from Physical Interaction), IMP
(Inferred from Mutant Phenotype), IGI (Inferred from Genetic
Interaction), IEP (Inferred from Expression Pattern), ISS (Inferred
from Sequence or Structural Similarity), and TAS (Traceable
Author Statement). We removed gene sets with more than 500
genes or fewer than 15, to exclude very broad categories or very
narrow ones, as suggested by the GSEA user guide [1].
Speciﬁcally, there are 1564 gene sets in the HSBP gene set
collection.
Parameter selection:We adopt a set of 8-fold change threshold
values (i.e., D ¼ 8) between the basic FC value (i.e., F1 ¼ 2) and the
mean of all FC values, i.e.,
FD ¼
PN
i¼1FCðgiÞ
N
ð14Þ
The other fold change threshold values are computed as follows:
Fj ¼ F1 þ j FD  F1D 1 ; j ¼ 2;3; . . . ;D 1 ð15Þ
Currently we set all entries of the weight matrixW to 1, in order
to avoid the parameter tuning problem.
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enrichment methods for signiﬁcant gene lists are used for compar-
ison with the proposed approach:
 Gene Set Enrichment Analysis based on pre-ranked gene list
(GseaPreRanked) [1], which runs Gene Set Enrichment
Analysis (GSEA) against a ranked list of genes and determines
whether a pre-deﬁned set of genes show statistically signiﬁcant
enrichment at either end of the ranking.
 Gene set categorization using Binomial Test (Binomial Test)
[39,40], which computes the statistical signiﬁcance of devia-
tions from a theoretically expected distribution of observations.
 Gene set categorization using Chi Square Test (Chi Square Test)
[41,40], which computes the value of the v2 statistic based on
the 2 2 contingency table.
 Gene set categorization using Fisher’s Exact test (Fisher’s Exact
test) [42,40], which computes a p-value against the hypothesis
that the number of positive cases observed or a more extreme
distribution might have occurred by chance given ﬁxed row
and column totals in the 2 2 contingency table.
 Adjusted Aggregation Score with Random Assignment
(Random), which assigns the genes to the D fold change ranges
at random and computes the adjusted aggregation score for
each gene set.
3.2. Experimental results: comparison with different methods based on
results of Gene Set Enrichment Analysis (GSEA) on studies with full
data
Currently there are no ground truth for gene set analysis for
human embryonic stem cell-derived cardiomyocytes (hESC-CMs).
Moreover, there are very few hESC-CM public gene data. As a
result, it is impractical to evaluate the signiﬁcance of the output
results only based on literature search. In view of this difﬁculty,
we perform GSEA on three studies with full data, including PO08
[12], PG12CWC3w [14], and PG12CWC7w [14]. We compare the
common proportions between results of each method with the
top 10% gene sets with the smallest FDR values of GSEA.
Speciﬁcally, assume there are Kc gene sets in both the top K ones
from a particular method and those from GSEA, the common pro-
portion is computed by KcK .
Results for the three studies are shown in Fig. 1. From Fig. 1, we
can observe that our proposed GSEE approach outperforms the
competitors in most cases. This suggests that our approach with
only signiﬁcant gene lists identiﬁes more enriched gene sets con-
ﬁrmed by GSEA with more informative data, even when compared
to GseaPreRanked which adopts similar techniques.
On the other hand we should mention the limitations of our
GSEE method when compared to GSEA: (1) GSEE is only advanta-
geous to use when only fold change data is available.
Development of GSEE when the full expression data set is available
should be carried on in future work; (2) GSEE cannot output
p-values for the investigated gene sets. Although this can be reme-
died by applying permutation of gene sets, the computation
burden will increase.0 100 200 300 400 500
0
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Fig. 1. Proportion of common top gene sets between outputs from various methods
based on signiﬁcant gene lists and those from GSEA based on full data matrices. The
proposed GSEE method outperforms other methods in most cases.3.3. Experimental results: signiﬁcant gene sets
For the GOBP gene set collection, GSEE evaluates each gene set
with the adjusted aggregation scores. The top 20 enriched gene
sets identiﬁed by GSEE in each study and their corresponding
scores are listed in Tables 2 and 3. We also performed GSEA to
check whether these gene sets are enriched based on the full data
from studies in the ﬁrst category as references, respectively, which
include: Reference 1 (R1): PO08 [12], Reference 2 (R2):PG12CWC3w [14], and Reference 3 (R3): PG12CWC7w [14].
Results of the complete gene set collection can be found in the sup-
plemental ﬁle 1 (S1). Observed from Tables 2 and 3, we can ﬁnd
that most of the top gene sets are conﬁrmed by GSEA based on full
data. On the other hand, some scarce gene sets enriched in
Table 2
Top 20 enriched gene sets identiﬁed by GSEE in each study with only signiﬁcant gene
lists. Numbers (1 or 0) in the last three columns represent whether or not the gene set
was identiﬁed in the GSEA analyses on the referenced studies, including R1(PO08),
R2(PG12CWC3w), and R3(PG12CWC7w).
Gene sets Score R1 R2 R3
(a) SC06
Ventricular cardiac muscle tissue morphogenesis 0.413 1 1 1
Regulation of atpase activity 0.401 1 1 1
Glomerulus development 0.381 1 1 0
Cardiac ventricle morphogenesis 0.378 1 1 1
Plasma lipoprotein particle remodeling 0.376 0 0 0
Plasma lipoprotein particle clearance 0.346 0 0 0
Phospholipid transport 0.338 0 0 0
Muscle ﬁlament sliding 0.332 1 1 1
Actin myosin ﬁlament sliding 0.332 1 1 1
Cardiac muscle tissue morphogenesis 0.331 1 1 1
Skin development 0.329 0 1 1
Muscle organ morphogenesis 0.315 1 1 1
Muscle tissue morphogenesis 0.315 1 1 1
Cholesterol efﬂux 0.311 0 0 0
Embryonic skeletal system development 0.303 0 1 1
Striated muscle contraction 0.301 1 1 1
Digestive tract morphogenesis 0.300 0 0 0
Cardiac muscle tissue development 0.298 1 1 1
Myoﬁbril assembly 0.293 1 1 1
Respiratory tube development 0.273 1 0 0
(b) SC08
Ventricular cardiac muscle tissue morphogenesis 0.326 1 1 1
Cardiac muscle tissue morphogenesis 0.272 1 1 1
Muscle ﬁlament sliding 0.264 1 1 1
Actin myosin ﬁlament sliding 0.264 1 1 1
Cardiac ventricle morphogenesis 0.263 1 1 1
Striated muscle contraction 0.262 1 1 1
Heart contraction 0.259 1 1 1
Muscle organ morphogenesis 0.254 1 1 1
Muscle tissue morphogenesis 0.254 1 1 1
Regulation of atpase activity 0.241 1 1 1
Actin ﬁlament based movement 0.206 1 1 1
Cardiac muscle tissue development 0.189 1 1 1
Cardiac muscle cell differentiation 0.168 1 1 1
Myoﬁbril assembly 0.162 1 1 1
Cardiac septum development 0.142 0 1 0
Regulation of heart contraction 0.139 1 1 1
Heart morphogenesis 0.139 1 1 1
Odontogenesis 0.139 0 1 0
Regulation of striated muscle contraction 0.139 0 1 1
Actomyosin structure organization 0.135 1 1 1
(c) SC09
Striated muscle contraction 0.462 1 1 1
Cardiac muscle tissue morphogenesis 0.458 1 1 1
Muscle organ morphogenesis 0.427 1 1 1
Muscle tissue morphogenesis 0.427 1 1 1
Ventricular cardiac muscle tissue morphogenesis 0.423 1 1 1
Myoﬁbril assembly 0.422 1 1 1
Heart contraction 0.402 1 1 1
Muscle ﬁlament sliding 0.380 1 1 1
Actin myosin ﬁlament sliding 0.380 1 1 1
Cardiac muscle tissue development 0.360 1 1 1
Actomyosin structure organization 0.353 1 1 1
Cardiac ventricle morphogenesis 0.345 1 1 1
Regulation of atpase activity 0.344 1 1 1
Cardiac muscle cell differentiation 0.330 1 1 1
Actin ﬁlament based movement 0.297 1 1 1
Regulation of heart contraction 0.283 1 1 1
Cardiac cell differentiation 0.268 1 1 1
Striated muscle cell development 0.268 1 1 1
Muscle ﬁber development 0.259 1 1 1
Muscle cell development 0.241 1 1 1
Table 3
Top 20 enriched gene sets identiﬁed by GSEE in each study with full data. Numbers (1
or 0) in the last three columns represent whether or not the gene set was identiﬁed in
the GSEA analyses on the referenced studies, including R1(PO08), R2(PG12CWC3w),
and R3(PG12CWC7w).
Gene sets Score R1 R2 R3
(a) PO08
Cardiac muscle tissue morphogenesis 0.455 1 1 1
Ventricular cardiac muscle tissue morphogenesis 0.450 1 1 1
Muscle organ morphogenesis 0.427 1 1 1
Muscle tissue morphogenesis 0.427 1 1 1
Muscle ﬁlament sliding 0.420 1 1 1
Actin myosin ﬁlament sliding 0.420 1 1 1
Striated muscle contraction 0.418 1 1 1
Myoﬁbril assembly 0.406 1 1 1
Heart contraction 0.392 1 1 1
Cardiac muscle tissue development 0.357 1 1 1
Hair follicle development 0.343 0 0 0
Regulation of atpase activity 0.341 1 1 1
Actomyosin structure organization 0.341 1 1 1
Cardiac ventricle morphogenesis 0.336 1 1 1
Actin ﬁlament based movement 0.328 1 1 1
Hair cycle process 0.321 1 0 0
Skin development 0.320 0 1 1
Cardiac muscle cell differentiation 0.316 1 1 1
Positive regulation of canonical Wnt receptor
signaling pathway
0.311 1 1 0
Cardiac cell differentiation 0.310 1 1 1
(b) PG12CMC3w
Myoﬁbril assembly 0.542 1 1 1
Ventricular cardiac muscle tissue morphogenesis 0.535 1 1 1
Cardiac muscle tissue morphogenesis 0.528 1 1 1
Cardiac muscle cell differentiation 0.506 1 1 1
Cardiac muscle tissue development 0.494 1 1 1
Muscle organ morphogenesis 0.494 1 1 1
Muscle tissue morphogenesis 0.494 1 1 1
Actomyosin structure organization 0.463 1 1 1
Heart contraction 0.442 1 1 1
Cardiac ventricle morphogenesis 0.408 1 1 1
Striated muscle cell development 0.400 1 1 1
Cardiac cell differentiation 0.394 1 1 1
Muscle ﬁlament sliding 0.391 1 1 1
Actin myosin ﬁlament sliding 0.391 1 1 1
Striated muscle contraction 0.358 1 1 1
Muscle tissue development 0.341 1 1 1
Skin development 0.336 0 1 1
Muscle cell development 0.326 1 1 1
Positive regulation of ﬁbroblast proliferation 0.315 0 0 0
Actin ﬁlament based movement 0.306 1 1 1
(c) PG12CMC7w
Myoﬁbril assembly 0.613 1 1 1
Actomyosin structure organization 0.528 1 1 1
Heart contraction 0.516 1 1 1
Cardiac muscle tissue morphogenesis 0.502 1 1 1
Ventricular cardiac muscle tissue morphogenesis 0.495 1 1 1
Muscle organ morphogenesis 0.482 1 1 1
Muscle tissue morphogenesis 0.482 1 1 1
Muscle ﬁlament sliding 0.479 1 1 1
Actin myosin ﬁlament sliding 0.479 1 1 1
Cardiac muscle cell differentiation 0.458 1 1 1
Cardiac muscle tissue development 0.448 1 1 1
Striated muscle contraction 0.435 1 1 1
Striated muscle cell development 0.421 1 1 1
Cardiac ventricle morphogenesis 0.388 1 1 1
Actin ﬁlament based movement 0.374 1 1 1
Cardiac cell differentiation 0.357 1 1 1
Muscle ﬁber development 0.346 1 1 1
Muscle cell development 0.341 1 1 1
Regulation of atpase activity 0.338 1 1 1
Regulation of heart contraction 0.330 1 1 1
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known to be related to cardiomyocytes-related functions, heart
disease, or related important organelle biogenesis in human
plasma, such as plasma lipoprotein particle remodeling
(go:0034369) [43,44], plasma lipoprotein particle clearance(go:0034381) [43,44], and phospholipid transport (go:0015914)
[45,46].
Among the top 20 gene sets from each study, it is interesting to
observe a large number of common ones. Analysis of gene sets
H. Huang et al. / Journal of Biomedical Informatics 57 (2015) 189–203 195enriched in multiple studies are shown in Table 4. Speciﬁcally,
there are ten gene sets (50%) uniquely enriched in all the studies,
and ﬁve enriched in ﬁve of the studies. The common gene sets
enriched in all the studies are shown in the ﬁrst ten rows in
Table 4. These enriched gene sets are related to known cardiac
functions such as heart contraction, heart development, regulation
and function, and more general biological processes such as muscle
morphogenesis and cell differentiation. Meta-analysis using the
aggregate evidence matrices of all of the hESC-CM data sets is also
performed, and the top 500 gene set list is shown in a supplemen-
tary ﬁle (S1 Table) in descending order of the corresponding GSEE
scores. It is interesting to observe that most of the top gene sets in
Table 4 have signiﬁcantly large scores in meta-analysis.
We perform further comparison on common signiﬁcant genes
and common enriched gene sets between the two study categories
with different kinds of data: (1) Studies with full gene data, includ-
ing PO08 [12], PG12CWC3w [14], and PG12CWC7w [14] and (2)
studies with signiﬁcant gene lists, including SC06 [10], SC08 [11],
and SC09 [13]. Venn diagrams are used to illustrate the distribu-
tions of common signiﬁcant genes and common enriched gene sets
for different numbers of top ones: (1) K = 50, (2) K = 150, and (3)
K = 300, respectively. As shown in Fig. 2 for the ﬁrst study category
with full gene data, we can ﬁnd that the numbers of common gene
sets are signiﬁcantly larger than those of common genes.
Speciﬁcally, 27 vs. 9 for K = 50, 68 vs. 35 for K = 150, and 144 vs.
72 for K = 300. Similar results can also be observed for the second
study category in Fig. 3. Speciﬁcally, 19 vs. 2 for K = 50, 56 vs. 7 forTable 4
Comparison of the top 20 enriched gene sets across all studies: s1:SC06, s2: SC08, s3:SC09,
where empty entities means the corresponding gene sets are not within the top 20 enrich
Gene set s1
Actin–myosin ﬁlament sliding 0.332
Cardiac muscle tissue development 0.298
Cardiac muscle tissue morphogenesis 0.331
Cardiac ventricle morphogenesis 0.378
Muscle ﬁlament sliding 0.332
Muscle organ morphogenesis 0.315
Muscle tissue morphogenesis 0.315
Myoﬁbril assembly 0.293
Striated muscle contraction 0.301
Ventricular cardiac muscle tissue morphogenesis 0.413
Actin ﬁlament-based movement
Actomyosin structure organization
Cardiac muscle cell differentiation
Heart contraction
Regulation of ATPase activity 0.401
Cardiac cell differentiation
Muscle cell development
Regulation of heart contraction
Skin development 0.329
Striated muscle cell development
Muscle ﬁber development
Cardiac septum development
Cholesterol efﬂux 0.311
Digestive tract morphogenesis 0.300
Embryonic skeletal system development 0.303
Glomerulus development 0.381
Hair cycle process
Hair follicle development
Heart morphogenesis
Muscle tissue development
Odontogenesis
Phospholipid transport 0.338
Plasma lipoprotein particle clearance 0.346
Plasma lipoprotein particle remodeling 0.376
Positive regulation of canonical Wnt receptor signaling pathway
Positive regulation of ﬁbroblast proliferation
Regulation of striated muscle contraction
Respiratory tube development 0.273K = 150, and 120 vs. 25 for K = 300. It can be observed that there are
only a small number of common signiﬁcant genes among different
studies, which might result from different experimental protocols,
such as hESC strains, differentiation conditions, culture duration
and microarray platform/thresholds used. This phenomenon is
more obvious in the second study category where only signiﬁcant
gene lists are provided. However, regardless of these experimental
protocols, similar enriched gene sets are obtained. Results of these
similar enriched gene sets from individual studies indicate that the
closely related nature of these studies, which cannot be extracted
from the comparison on genes.
3.4. Experimental results: pairwise study comparison
We performed pairwise study comparison based on signiﬁcant
genes and enriched gene sets for different number of top K ones:
(1) K = 50, (2) K = 150, and (3) K = 300. Comparison results based
on genes are shown in Fig. 4(a)–(c), while those based on gene sets
are shown in Fig. 4(d)–(f).
Interestingly, we can observe that similarity on gene sets is
more signiﬁcant than that on genes. Notably, although there are
very small proportions of common signiﬁcant genes between
SC09 and other studies in top K = 50 ones (last column in
Fig. 4(a)), the gene set based similarity values between it and the
other studies is comparable to those of others (last column in
Fig. 4(d)). As hESC-CMs are puriﬁed in SC09, the important
hESC-CM related gene sets are extracted based on the smallers4:PO08, s5:PG12CWC3w, and s6:PG12CWC7w. GSEE scores are shown in the entities,
ed gene sets in the investigated studies.
s2 s3 s4 s5 s6
0.264 0.380 0.420 0.391 0.479
0.189 0.360 0.357 0.494 0.448
0.272 0.458 0.455 0.528 0.502
0.263 0.345 0.336 0.408 0.388
0.264 0.380 0.420 0.391 0.479
0.254 0.427 0.427 0.494 0.482
0.254 0.427 0.427 0.494 0.482
0.162 0.422 0.406 0.542 0.613
0.262 0.462 0.418 0.358 0.435
0.326 0.423 0.450 0.535 0.495
0.206 0.297 0.328 0.306 0.374
0.135 0.353 0.341 0.463 0.528
0.168 0.330 0.316 0.506 0.458
0.259 0.402 0.392 0.442 0.516
0.241 0.344 0.341 0.338
0.268 0.310 0.394 0.357
0.241 0.326 0.341
0.139 0.283 0.330
0.320 0.336
0.268 0.400 0.421
0.259 0.346
0.142
0.321
0.343
0.139
0.341
0.139
0.311
0.315
0.139
Fig. 2. Venn diagrams of the top K genes in three studies with full data matrices: (a) K = 50, (b) K = 150, (c) K = 300; Venn diagrams of the top K gene sets identiﬁed by GSEE in
three studies with full data matrices: (d) K = 50, (e) K = 150, (f) K = 300.
196 H. Huang et al. / Journal of Biomedical Informatics 57 (2015) 189–203but also important genes. Another interesting observation is the
irrelevance of similarity between genes and that between gene sets
with different number of top K ones. We can observe that gene set
based similarity values are not necessarily proportional to those of
single genes. For similarity between PO08 and PG12CWC3w, thegene based similarity values increase according to K values (0.26,
0.28, 0.29 for K = 50, 150, 300, respectively), while gene set based
similarity values vary (0.58, 0.55, and 0.62 correspondingly).
These observations indicate that gene set based similarity can
provide new insights on the comparison of different hESC-CM studies.
Fig. 3. Venn diagrams of the top K genes in there studies with only signiﬁcant expressed gene lists: (a) K = 50, (b) K = 150, (c) K = 300; Venn diagrams of the top K gene sets
identiﬁed by GSEE in three studies with only signiﬁcant expressed gene lists: (d) K = 50, (e) K = 150, (f) K = 300.
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proportions of signiﬁcant genes
We also performed a robustness test of our GSEE approach with
different proportions of removal of signiﬁcant genes. Speciﬁcally,for each study, we removed different proportions of signiﬁcant
genes at random from the original list, and compared the GSEE
results on these reduced gene lists to those on the original full lists.
Results on the studies from the two categories are shown in Figs. 5
and 6, respectively. We performed 10 trials for each proportion,
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Fig. 4. Common proportions of the top K genes for each study pair: (a) K = 50, (b) K = 150, (c) K = 300; Common proportions of the top K gene sets for each study pair: (d)
K = 50, (e) K = 150, (f) K = 300.
198 H. Huang et al. / Journal of Biomedical Informatics 57 (2015) 189–203and compare the results in the top gene sets for K = 50, 150, and
300, respectively. The similarity proportions between the enriched
gene sets of reduced gene lists and those of the full gene lists
gradually decrease with the increased extent of removal, and the
standard error values also increase. Notably, the similarity
proportions are signiﬁcantly large, and most of the values arelarger than 0.8. This suggests that our GSEE approach could ﬁnd
at least 80% of the enriched gene sets even with 20% of the
signiﬁcant genes are removed from the original gene list. This is
an important observation since a lot of genes might be ﬁltered
out from different studies and the numbers of common genes
could be quite small (as shown in Figs. 2 and 3).
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Fig. 5. Robustness test of GSEE in studies with full data matrices. Proportion of common top gene sets identiﬁed by full gene lists and those of reduced one with different
random removal percentages which decrease gradually. Notably, all the proportions are signiﬁcantly large.
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fold change threshold values
We also performed a robustness test of our GSEE approach with
different numbers of fold change threshold values, i.e., D in (3).
Speciﬁcally, we use several different settings as follows, D ¼ 4, 8,
12, 16 for the three studies with full gene expression data
(PG12CMC3w, PG12CMC7w and PO08). The proportion of identical
gene sets in the top 150 gene sets identiﬁed by our studies with
different settings are shown in Fig. 7. Results with different num-
bers of fold change threshold values for the same studies are
shown in the diagonal blocks, and those with different numbers
of fold change threshold values for different studies are shown in
the off-diagonal ones. The numbers in the diagonal blocks are very
high, and they generally increase with D, e.g., the proportion value
between PG12CMC3wD04 and PG12CMC3wD08 is 0.97, and it
becomes 0.98 (PG12CMC3wD08 and PG12CMC3wD12) and 0.99(PG12CMC3wD12 and PG12CMC3wD16) when D increases. Also,
the proportion values for the same rows (or columns) in the
off-diagonal blocks are quite similar. These suggest that the identiﬁed
top gene sets by our GSEE approach for each study are not sensitive
to the different number of fold change threshold values.3.7. Experimental results: robustness test with different levels of the
lower fold change threshold values
We also performed a robustness test of our GSEE approach with
different levels of the lower fold change threshold values, i.e., F1 in
(3). Speciﬁcally, we use several different settings as follows, F1 ¼ 1,
2, 3, 4) for the three studies with full gene expression data
(PG12CMC3w, PG12CMC7w and PO08). The proportion of identical
gene sets in the top 150 gene sets identiﬁed by studies with differ-
ent settings are shown in Fig. 8. Comparison results for the same
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Fig. 6. Robustness test of GSEE in studies with only signiﬁcant gene lists. Proportion of common top gene sets identiﬁed by full gene lists and those of reduced one with
different random removal percentages decrease gradually. Notably, all the proportions are signiﬁcantly large.
200 H. Huang et al. / Journal of Biomedical Informatics 57 (2015) 189–203studies are shown in the diagonal blocks, and those for different
studies are shown in the off-diagonal ones.
The numbers in the diagonal blocks are fairly high, and they
generally increase with F1, e.g., the proportion value between
PG12CMC3wL01 and PG12CMC3wL02 is 0.70, and it becomes
0.78 (PG12CMC3wL02 and PG12CMC3wL03) and 0.87
(PG12CMC3wL03 and PG12CMC3wL04) when F1 increases. Also,
the proportion values for the same rows (or columns) in the
off-diagonal blocks are also close. These suggest that the identiﬁed
top gene sets by our GSEE approach for each study are not sensitive
to the different levels of the lower fold change threshold values. On
the other hand, compared to the effect of numbers of fold change
threshold values (i.e., D), we can observe that the lower fold change
threshold values are more important to the results. This suggests
that more genes will be considered in our GSEE approaches if the
lower fold change threshold value decreases.3.8. Experimental results with fetal heart data: comparison with
different methods based on results of Gene Set Enrichment Analysis
(GSEA) on studies with full data
We also performed experiments on fetal heart data from
PO08 [12] and PG12 [14], respectively. Signiﬁcant gene list with
fetal heart over undifferentiated embryonic stem cells are used
as input for our GSEE approach and the competitors, and GSEA
results based on full expression data are used as the reference.
The lower fold change threshold values are set to F1 ¼ 2 and
the number of threshold values are set to D ¼ 8. Proportion
curves are shown in Fig. 9. From Fig. 9, we can observe that
our proposed GSEE method outperforms other methods in most
cases. Speciﬁcally, in Fig. 9(a), GSEE outperforms all the other
competitors in all cases except for the Fisher Exact Test
method. It is interesting to observe that GSEE is better than
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Fig. 7. Experimental results: Robustness test with different numbers of fold change threshold values. Results with different numbers of fold change threshold values for the
same studies are shown in the diagonal blocks, and those with different numbers of fold change threshold values for different studies are shown in the off-diagonal ones.
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Fig. 8. Experimental results: Robustness test with different levels of the lower threshold values. Results with different levels of the lower fold change threshold values for the
same studies are shown in the diagonal blocks, and those for different studies are shown in the off-diagonal ones.
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of investigated gene sets. The performance of GSEE on PG12
is shown in Fig. 9(b), and we can see that GSEE signiﬁcantly
outperforms its competitors.4. Conclusion
In this paper, we have proposed a new Gene Set Enrichment
Ensemble method (GSEE) which uses fold change data only.
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Fig. 9. Proportion of common top gene sets between outputs from various methods
based on signiﬁcant gene lists and those from GSEA based on full data matrices for
fetal heart data. The proposed GSEE method outperforms other methods in most
cases.
202 H. Huang et al. / Journal of Biomedical Informatics 57 (2015) 189–203Speciﬁcally, we use the signiﬁcant gene lists associated with their
fold change (FC) data as the input, and propose a new adjusted
aggregation score to evaluate different enrichment of gene sets
from user-deﬁned gene set collections. Our method utilizes the
FC data to implicitly assign different weights for genes with differ-
ent degrees of signiﬁcance. The main contributions of our work
thus include: (a) In terms of computation, we proposed a new gene
set analysis method based on signiﬁcant gene lists and their fold
change (FC) data. (b) In terms of biological signiﬁcance, to our best
knowledge, we performed the ﬁrst investigation of different
hESC-CM studies of diverse variations.
We compare our approach with several previous gene set anal-
ysis methods based on signiﬁcant gene lists. A number of interest-
ing observations are obtained from the hESC-CM studies: (1) Our
GSEE method largely outperforms popular Gene Set based analysis
competitors by extracting more common enriched gene sets with
those from GSEA based on full gene data; (2) Our GSEE method
identiﬁes enriched gene sets that are meaningful in terms of bio-
logical functions; (3) Gene set based analysis based on our GSEE
results discovers much more commonly enriched gene sets among
individual studies than common genes, regardless of their diverse
variations; (4) Our GSEE method is robust under different settings
of parameters.Although we perform our GSEE method using up-regulated
genes with fold change data only, it is also interesting to study
down-regulated genes as well. Study on these two types of signif-
icant genes with GSEE can be conducted in the same manner.
Investigation from both perspectives might help to gain deeper
insight into the related gene regulatory mechanisms and biological
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